SCHEMBL218837

SCHEMBL218837

Cc1cccc(N2CCNCC2)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 4/20 1.00
HTR1A P08908 5/20 0.67
HTR3A P46098 5/20 0.67
CYP1A2 P05177 3/20 0.67
CYP2D6 P10635 3/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2C9 P11712 2/20 0.67
HTR7 P34969 2/20 0.64
ALDH1A1 P00352 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
TSHR P16473 2/20 0.54
MAPK1 P28482 1/20 0.54
HTR6 P50406 4/20 0.54
DRD2 P14416 1/20 0.53
DRD3 P35462 1/20 0.53
HTR3E A5X5Y0 1/20 0.53
HTR3B O95264 1/20 0.53
NCF1 P14598 1/20 0.53
NFKB1 P19838 1/20 0.53
HTR1D P28221 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29699369 1.00 ADRB1 (1.00) ADRB1HTR1AHTR3ACYP1A2CYP2D6
Hydrochloric Acid SCHEMBL27850954 0.98 ADRB1 (0.96) ADRB1HTR1AHTR3ACYP1A2CYP2D6
Piperazine SCHEMBL27593403 0.98 ADRB1 (0.96) ADRB1HTR1AHTR3ACYP1A2CYP2D6
Iodide SCHEMBL11457680 0.98 ADRB1 (0.96) ADRB1HTR1AHTR3ACYP1A2CYP2D6
Hydrochloric Acid SCHEMBL1894847 0.98 ADRB1 (0.96) ADRB1HTR1AHTR3ACYP1A2CYP2D6
SCHEMBL9310335 0.93 ADRB1 (0.87) ADRB1HTR1AHTR3ACYP1A2CYP2D6
SCHEMBL7487422 0.90 ADRB1 (0.81) ADRB1HTR1AHTR3ACYP1A2CYP2D6
SCHEMBL27868178 0.90 ADRB1 (0.81) ADRB1HTR1AHTR3ACYP1A2CYP2D6
SCHEMBL11067105 0.86 ADRB1 (0.74) ADRB1ALDH1A1NPSR1TSHRMAPK1
SCHEMBL7979300 0.85 ADRB1 (0.74) ADRB1HTR1AHTR3ACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026696-A1 Novel Humic Material and Method to Formulate the Same MEYER MICHAEL J (US) 2025-01-23 US claimed
US-20230078902-A1 Novel Method to Formulate Humic Substances MEYER MICHAEL J (US) 2023-03-16 US claimed
WO-2023279162-A1 METHODS OF TREATMENT AND INHIBITION UNIVERSITY OF CANBERRA (AU) 2023-01-12 WO claimed
US-11548833-B2 Method to formulate humic substances MEYER MICHAEL J (US) 2023-01-10 US claimed
US-20200385320-A1 Method to Formulate Humic Substances MEYER MICHAEL J (US) 2020-12-10 US claimed
US-10568852-B2 Combination compositions and their use in methods for treating obesity and obesity-related disorders HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-02-25 US claimed
CN-104311519-B Functional food factor preparation and its application with mucosal lesion protective effect 山东理工大学 2018-12-18 CN claimed
US-20180147163-A1 COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) 2018-05-31 US claimed
EP-3297676-A2 COMBINATION OF TRPM8-AGONIST AND NACHR-AGONIST FOR TREATMENT OF OBESITY AND RELATED DISORDERS AND FOR WEIGHT REDUCTION Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2018-03-28 EP claimed
US-20170348430-A1 MICELAR DELIVERY SYSTEM BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID RAMOT AT TEL AVIV UNlVERSITY LTD. (IL) 2017-12-07 US claimed
WO-2005016902-A1 N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES ARENA PHARMACEUTICALS, INC. (US) 2005-02-24 WO claimed
JP-2004523588-A 2004-08-05 JP claimed
US-20040132737-A1 Nicotinic receptor agonists for the treatment of inflammatory diseases UNIVERSITE LAVAL (CA) 2004-07-08 US claimed
CN-1498108-A Nicotinic receptor agonists for treatment of inflammatory diseases �Ϻ���ͨ��ѧ 2004-05-19 CN claimed
EP-1370264-A2 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES Université Laval (CA) 2003-12-17 EP claimed
WO-2002076434-A2 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES UNIVERSITE LAVAL (CA) 2002-10-03 WO claimed
WO-2002059093-A1 METHODS AND COMPOSITIONS FOR BINDING NUCLEIC ACID MOLECULES GENESPAN CORPORATION (US) 2002-08-01 WO claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0615855-B1 Recording sheets containing pyridinium and/or piperazinum compounds XEROX CORP (US) 1997-05-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10568852-B2 Combination compositions and their use in methods for treating obesity and obesity-related disorders FABP4, LIPC, GPR119 ADRB1 668/4885HTR1A 1418/4885HTR3A 872/4885
US-20180147163-A1 COMBINATION COMPOSITIONS AND THEIR USE IN METHODS FOR TREATING OBESITY AND OBESITY-RELATED DISORDERS FABP4, LIPC, GPR119 ADRB1 668/4885HTR1A 1418/4885HTR3A 872/4885
US-20170348430-A1 MICELAR DELIVERY SYSTEM BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID KIT, JMJD7, LIPA ADRB1 3908/4885HTR1A 4157/4885HTR3A 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.